

PATENT
Customer No. 22,852
Attorney Docket No. 09095.0006-01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)	
)	
Indrani W. GUNAWARDANA)	Group Art Unit: 1624
)	
Application No.: 10/725,212)	Examiner: S. Patel
)	
Filed: December 1, 2003)	
)	
For: CELL ADHESION-INHIBITING)	
ANTI-INFLAMMATORY AND)	
IMMUNE-SUPPRESSIVE)	
COMPOUNDS)	

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(c)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(c), applicant brings to the attention of the Examiner the documents listed on the attached PTO 1449. This Information Disclosure Statement is being filed after the events recited in Section 1.97(b) but, to the undersigned's knowledge, before the mailing date of either a Final action, Quayle action, or a Notice of Allowance. Under the provisions of 37 C.F.R. § 1.97(c), this Information Disclosure Statement is accompanied by a fee of \$180.00 as specified by Section 1.17(p).

Applicants' representative contacted Examiner Patel, the Examiner of parent patent application 09/695,040, on January 28, 2004 regarding citing art that was previously cited in the parent applications. The Examiner informed Applicants'

Application No.: 10/725,212
Attorney Docket No. 09095.0006-01

representative that it would be acceptable to not provide copies of the previously cited art. The documents shown with an asterisk (*) were cited in a parent application and therefore copies of these references are not enclosed; copies of all other listed documents are enclosed.

Applicants respectfully request that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in the application and Applicants determine that the cited documents do not constitute "prior art" under United States law, Applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such documents.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.


Application No.: 10/725,212
Attorney Docket No. 09095.0006-01

If there is any fee due in connection with the filing of this Statement, please
charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: September 7, 2004

By:  Reg. No. 52,516
Maria T. Bautista
Reg. No. 52,516

OMB No. 0651-0011

INFORMATION DISCLOSURE CITATION

Atty. Docket No.	09095.0006-01000	Appln. No.	10/725,212
Applicant	Indrani W. GUNAWARDANA		
Filing Date	December 1, 2003	Group:	1624

U.S. PATENT DOCUMENTS						
Examiner Initial*	Document Number	Issue Date	Name	Class	Sub Class	Filing Date If Appropriate
	Publication No. US 2001/0031260 A1	Published 10/18/2001	Lee et al.	424	145.1	12/14/2000
	Publication No. US 2002/0037895 A1	Published 03/28/2002	Baenteli et al.	514	228.8	08/13/2001
	Publication No. US 2002/0039577 A1	Published 04/04/2002	Townsend et al.	424	131.1	06/08/2001
	Publication No. US 2002/0107241 A1	Published 08/08/2002	Lauffer et al.	514	217.12	01/03/2002
	Publication No. US 2002/0119994 A1	Published 08/29/2002	Burdick et al.	514	316	11/26/2001
	Publication No. US 2002/0132807 A1	Published 09/19/2002	Wang et al.	514	227.5	08/25/2001
	Publication No. US 2002/0156314 A1	Published 10/24/2002	Link et al.	558	414	06/25/2001
	Publication No. US 2002/0065007 A1	Published 04/03/2003	Creswell et al.	514	307	10/09/2002
	Publication No. US 2003/0069238 A1	Published 04/10/2003	Barrish et al.	514	235.5	12/20/2001
	Publication No. US 2003/0087903 A1	Published 05/08/2003	Baentell et al.	514	228.8	07/11/2002
	Publication No. US 2003/0088061 A1	Published 05/08/2003	Staunton	530	350	10/12/2001
	3,576,872	04/27/1971	Singhal	260	562	05/03/1988
	3,948,893	04/08/1976	Alchinger et al.	260	248	03/18/1974
	4,044,133	08/23/1977	Rogers et al.	424	251	10/16/1975
	4,275,077	06/23/1981	Becher et al.	424	322	01/08/1980
	4,731,368	03/15/1988	Hoffman, Jr. et al.	514	301	12/08/1986
	4,775,757	10/04/1988	Kanojia et al.	544	362	09/22/1986
	* 4,808,582	02/28/1989	Platel et al.	514	212	03/19/1987
	4,927,807	05/22/1990	Stein et al.	514	18	09/08/1988
	* 4,973,599	11/27/1990	Gilman et al.	514	398	03/14/1989
	5,006,532	04/09/1991	Baker et al.	514	301	12/08/1989

OMB No. 0651-0011

INFORMATION DISCLOSURE CITATION

Atty. Docket No.	09095.0006-01000	Appln. No.	10/725,212
Applicant	Indrani W. GUNAWARDANA		
Filing Date	December 1, 2003	Group:	1624

U.S. PATENT DOCUMENTS							
Examiner Initial*		Document Number	Issue Date	Name	Class	Sub Class	Filing Date If Appropriate
	*	5,028,629	07/02/1991	Hite et al.	514	575	03/28/1990
	*	5,034,417	07/23/1991	Matsuo et al.	514	605	05/24/1988
		5,036,051	07/30/1991	Stein et al.	514	18	03/02/1990
		5,100,378	03/31/1992	Morgan Jr.	604	49	06/09/1989
	*	5,208,253	05/04/1993	Boschelli et al.	514	443	02/24/1992
		5,235,049	08/10/1993	McClelland et al.	435	240.2	01/24/1989
		5,242,687	09/07/1993	Tykocinski et al.	424	93	04/25/1991
		5,252,581	10/12/1993	Effland et al.	514	301	07/20/1992
		5,256,648	10/26/1993	Gasparro et al.	514	44	09/21/1989
		5,288,854	02/22/1994	Diamond et al.	530	395	11/28/1990
		5,322,699	08/21/1994	Wright et al.	424	534	02/04/1991
		5,395,929	03/07/1995	Corbi et al.	536	23.5	05/27/1993
		5,442,060	08/15/1995	Jikihara et al.	544	106	09/29/1993
		5,512,660	04/30/1996	Springer et al.	530	395	02/10/1994
		5,547,853	08/20/1996	Wallner et al.	435	69.1	10/21/1992
		5,565,550	10/15/1996	Springer et al.	530	391.3	02/10/1994
		5,576,460	11/19/1996	Buchwald et al.	564	386	07/27/1994
		5,589,453	12/31/1996	Greve	514	8	09/30/1994
		5,597,567	01/28/1997	Whitcup et al.	424	143.1	02/04/1994
		5,597,823	01/28/1997	Meyer et al.	514	250	06/05/1995
		5,599,676	02/04/1997	Vonderheide et al.	435	7.2	10/14/1994
		5,622,700	04/22/1997	Jardieu et al.	424	144.1	05/02/1995
		5,629,162	05/13/1997	deFougerolles et al.	435	7.1	06/07/1995
		5,674,982	10/07/1997	Greve et al.	530	388.22	06/05/1995
		5,686,265	11/11/1997	Corbi et al.	435	69.1	12/30/1994
		5,686,279	11/11/1997	Finer et al.	435	172.3	06/10/1994
		5,686,581	11/11/1997	Greve et al.	530	402	06/05/1995

OMB No. 0651-0011

INFORMATION DISCLOSURE CITATION

Atty. Docket No.	09095.0006-01000	Appln. No.	10/725,212
Applicant	Indrani W. GUNAWARDANA		
Filing Date	December 1, 2003	Group:	1624

U.S. PATENT DOCUMENTS						
Examiner Initial*	Document Number	Issue Date	Name	Class	Sub Class	Filing Date If Appropriate
	5,686,582	11/11/1997	Greve et al.	530	402	06/05/1995
	5,707,985	01/13/1998	McKenzie et al.	514	183	06/07/1995
	5,726,037	03/10/1998	Bodary et al.	435	69.1	05/19/1995
	5,726,290	03/10/1998	Bodary et al.	530	350	05/19/1995
	5,728,677	03/17/1998	Wallner et al.	514	12	06/02/1995
	5,730,983	03/24/1998	Wegner et al.	424	185.1	05/19/1994
	5,739,032	04/14/1998	Springer et al.	435	320.1	04/06/1994
	5,747,035	05/05/1998	Presta et al.	424	144.1	04/14/1995
	5,762,933	06/09/1998	Mawas et al.	424	154.1	10/17/1994
	5,770,686	06/23/1998	Gallatin et al.	530	300	06/07/1995
	* 5,776,951	07/07/1998	Arrowsmith et al.	514	328	04/11/1996
	* 5,817,862	10/06/1998	Poetsch et al.	560	104	08/22/1996
	5,821,341	10/13/1998	McClelland et al.	530	388.22	05/18/1995
	5,827,857	10/27/1998	Riedl et al.	514	301	01/09/1997
	5,830,880	11/03/1998	Sedlacek et al.	514	44	04/18/1997
	5,831,036	11/03/1998	Springer et al.	530	395	10/25/1993
	5,834,256	11/10/1998	Finer et al.	435	91.33	06/11/1993
	5,834,266	11/10/1998	Crabtree et al.	435	172.3	08/18/1994
	5,834,468	11/10/1998	Breault et al.	514	247	07/02/1996
	5,837,478	11/17/1998	Gallatin et al.	435	7.24	10/03/1997
	5,837,486	11/17/1998	Bodary et al.	435	69.1	05/19/1995
	5,840,732	11/24/1998	Takatani et al.	514	300	12/06/1996
	5,849,699	12/15/1998	McClelland et al.	514	12	04/20/1995
	5,852,170	12/22/1998	Kilgannon et al.	530	350	06/07/1995
	5,854,070	12/29/1998	Rose	435	343.2	01/21/1997
	5,859,212	01/12/1999	McClelland et al.	530	413	05/18/1995
	5,863,889	01/26/1999	Benedict et al.	514	2	11/19/1996

OMB No. 0651-0011

INFORMATION DISCLOSURE CITATION

Atty. Docket No.	09095.0006-01000	Appln. No.	10/725,212
Applicant	Indrani W. GUNAWARDANA		
Filing Date	December 1, 2003	Group:	1624

U.S. PATENT DOCUMENTS						
Examiner Initial*	Document Number	Issue Date	Name	Class	Sub Class	Filing Date If Appropriate
	5,869,262	02/09/1999	Gallatin et al.	435	7.1	06/07/1995
	5,869,337	02/09/1999	Crabtree et al.	435	372.3	02/14/1995
	5,871,733	02/16/1999	Greve et al.	424	134.1	06/05/1995
	5,883,082	03/16/1999	Bennett et al.	514	44	11/23/1994
*	5,883,106	03/16/1999	Stevens et al.	514	277	02/06/1998
*	5,883,133	03/16/1999	Schwark et al.	514	619	07/24/1996
	5,888,508	03/30/1999	Hildreth	424	130.1	02/07/1996
	5,891,841	04/08/1999	deFougerolles et al.	514	2	06/07/1995
*	5,912,266	06/15/1999	Perez	514	460	08/13/1997
	5,916,910	06/29/1999	Lai	514	423	06/04/1997
	5,919,754	07/06/1999	Altieri et al.	514	2	11/12/1996
	5,928,643	07/27/1999	Wallner et al.	424	134.1	06/02/1995
	5,932,214	08/03/1999	Lobb et al.	424	144.1	10/15/1997
	5,935,585	08/10/1999	Bernardon et al.	424	401	02/23/1996
	5,948,758	09/07/1999	Springer et al.	514	12	03/04/1997
	5,983,279	11/09/1999	Lin et al.	709	235	08/30/1996
	6,001,651	12/14/1999	Bennett et al.	435	375	03/20/1998
	6,001,809	12/14/1999	Thorsett et al.	514	15	06/06/1995
	6,011,018	01/04/2000	Crabtree et al.	514	31	05/29/1998
	6,013,674	01/11/2000	Morin, Jr. et al.	514	621	05/01/1998
	6,030,947	02/29/2000	Corbi et al.	514	12	03/19/1997
	6,037,454	03/14/2000	Jardieu et al.	530	387.3	11/20/1997
	6,043,284	03/28/2000	Arrowsmith et al.	514	621	02/05/1998
	6,051,231	04/18/2000	Greve et al.	424	185.1	09/30/1994
	6,083,751	07/04/2000	Feldhaus et al.	435	372.3	11/01/1995
	6,096,862	08/01/2000	Greve et al.	530	324	10/04/1994
	6,096,871	08/01/2000	Presta et al.	530	387.3	04/14/1995

OMB No. 0651-0011

INFORMATION DISCLOSURE CITATION

Atty. Docket No.	09095.0006-01000	Appln. No.	10/725,212
Applicant	Indrani W. GUNAWARDANA		
Filing Date	December 1, 2003	Group:	1624

U.S. PATENT DOCUMENTS

Examiner Initial*	Document Number	Issue Date	Name	Class	Sub Class	Filing Date If Appropriate
	* 6,110,922	08/29/2000	Link et al.	514	259	12/29/1998
	6,121,022	09/19/2000	Presta et al.	435	69.7	04/14/1995
	6,130,202	10/10/2000	Greve et al.	514	12	04/14/1994
	6,143,298	11/07/2000	Greve et al.	424	185.1	05/05/1995
	6,162,432	12/19/2000	Wallner et al.	424	154.1	06/06/1995
	6,180,624 B1	01/30/2001	Hill	514	227.5	02/25/1999
	6,187,308 B1	02/13/2001	Hildreth	424	130.1	11/20/1998
	6,211,215 B1	04/03/2001	Momose et al.	514	374	11/18/1998
	6,214,342 B1	04/10/2001	Alberici et al.	424	154.1	10/30/1995
	6,218,187 B1	04/17/2001	Finer et al.	435	457	03/11/1999
	* 6,329,362 B1	12/11/2001	Archibald et al.	514	188	03/16/1999
	6,399,599 B1	06/04/2002	Albert et al.	514	218	10/11/2000
	6,448,247 B1	09/10/2002	Nishi et al.	514	233.5	03/22/2000
	6,521,619 B2	02/18/2003	Link et al.	514	237.2	06/25/2001
	6,599,506 B1	07/29/2003	Nozawa et al.	424	185.1	04/20/2000
	* S/N 09/285,325		Fowler, et al.			04/02/1999
	* S/N 09/541,795		Link et al.			03/31/2000
	S/N 09/695,040		Gunawardana			10/24/2000

FOREIGN PATENT DOCUMENTS

Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No
* DE 2 123 383	02/12/1971	Germany	C07B	29/00	No TRANSLATION CITED BY SHELDON & MAK BUT WE DO NOT HAVE A COPY
* EP 0 219 756 A1	04/29/1987	Europe	C07D	295/18	No

OMB No. 0651-0011

INFORMATION DISCLOSURE CITATION

Atty. Docket No.	09095.0006-01000	Appln. No.	10/725,212
Applicant	Indrani W. GUNAWARDANA		
Filing Date	December 1, 2003	Group:	1624

FOREIGN PATENT DOCUMENTS							
		Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No
	*	EP 0 292 979 B1	07/21/1993	Europe	C07C	311/08	
	*	EP 0 835 867 A1	04/15/1998	Europe	C07D	295/08	
	*	EP 0 887 340 A1	12/30/1998	Europe	C07C	235/34	
	*	GB 2 117 760 A	10/19/1983	United Kingdom	C07D	213/62	
	*	JP 2000-72766	03/07/2000	Japan	C07D	311/58	No
	*	WO 98/13347	04/02/1998	PCT	C07D	213/53	
	*	WO 98/39303	09/11/1998	PCT	C07D	233/76	
	*	WO 98/54207	12/03/1998	PCT	C07K	5/06	
	*	WO 99/11258	03/11/1999	PCT	A61K	31/365	
	*	WO 99/20617	04/29/1999	PCT	C07D	285/12	
	*	WO 99/20618	04/29/1999	PCT	C07D	285/135	
	*	WO 99/49856	10/07/1999	PCT	A61K	31/00	
	*	WO 00/15804	03/23/2000	PCT	C07C	235/20	No
	*	WO 00/15645	03/23/2000	PCT	C07F	9/572	No
	*	WO 00/21920	04/20/2000	PCT	C07C	235/52	
	*	WO 00/39081	07/06/2000	PCT	C07C	323/00	
	*	WO 00/48989	08/24/2000	PCT	C07C	235/26	
	*	WO 01/06984 A2	02/01/2001	PCT	A61K		
	*	WO 01/07052 A1	02/01/2001	PCT	A61K	31/55	
	*	WO 01/27102 A1	04/19/2001	PCT	C07D	401/06	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
	* International Search Report for International Patent Application No. PCT/US00/08895, mailed August 7, 2000
	* Ali et al., "Mechanisms of Inflammation and Leukocyte Activation", <i>Med. Clin. North America</i> , 81:1-28 (1997)
	* Aoudjit et al., "Protection from Lymphoma Cell Metastasis in ICAM-1 Mutant Mice: A Posthomologous Event", <i>J. Immunol.</i> , 161:2333-2338 (1998)

OMB No. 0651-0011

INFORMATION DISCLOSURE CITATION

Atty. Docket No.	09095.0006-01000	Appln. No.	10/725,212
Applicant	Indrani W. GUNAWARDANA		
Filing Date	December 1, 2003	Group:	1624

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	* Bella et al., "The Structure of the Two Amino-Terminal Domains of Human ICAM-1 Suggests How It Functions as a Rhinovirus Receptor and as an LFA-1 Integrin Ligand", <i>PNAS</i> , 95:4140-4145 (1998)
	* Bennett et al., "An ICAM-1 Antisense Oligonucleotide Prevents and Reverses Dextran Sulfate Sodium-Induced Colitis in Mice", <i>J. Pharmacology Exper. Therapeutics</i> , 280:988-1000 (1997)
	* Berge et al., "Pharmaceutical Salts", <i>J. Pharmaceutical Sciences</i> , 66:1-19 (1977)
	* Bicking et al., "(Vinylaryloxy) acetic Acids. A New Class of Diuretic Agents. (Diacylvinyloxy) acetic Acids", <i>J. Medicinal Chem.</i> , 19:530-535 (1976)
	* Blinnerts et al., "How LFA-1 Binds to Different Ligands", <i>Immunol. Today</i> , 20:240-245 (1999)
	* Bloemen et al., "LFA-1, and Not Mac-1, is Crucial for the Development of Hyperreactivity in a Murine Model of Nonallergic Asthma", <i>Am. J. Respir. Crit. Med.</i> , 153:521-529 (1996)
	* Boschelli et al., "Inhibition of E-Selectin-, ICAM-1-, and VCAM-1-Mediated Cell Adhesion by Benzo[b]thiophene-, Benzofuran-, Indole-, and Naphthalene-2-Carboxamides: Identification of PD 144795 as an Antiinflammatory Agent", <i>J. Med. Chem.</i> , 38:4597-4614 (1995)
	* Carlos et al., "Leukocyte-Endothelial Adhesion Molecules", <i>Blood</i> , 84:2068-2101 (1994)
	* Chambers et al., "Polyhalogenated Heterocyclic Compounds. Part 41. Cycloaddition Reactions Involving Hexafluorobut-2-yne and 1,1,1,2,4,4,4-heptafluorobut-2-ene", <i>J. Chem. Soc., Perkin Trans.</i> , 1:1095-1100 (1996)
	* Chopp et al., "Postischemic Administration of an Anti-Mac-1 Antibody Reduces Ischemic Cell Damage After Transient Middle Cerebral Artery Occlusion in Rats", <i>Stroke</i> , 25:869-876 (1994)
	* Clark et al., "Reduction of Central Nervous System Ischemic Injury by Monoclonal Antibody to Intercellular Adhesion Molecule", <i>J. Neurosurg.</i> , 75:623-627 (1991)
	* Cosimi et al., "In Vivo Effects of Monoclonal Antibody to ICAM-1 (CD54) In Nonhuman Primates with Renal Allografts", <i>J. Immunol.</i> , 144:4604-4612 (1990)
	* DeMeester et al., "Attenuation of Rat Lung Isograft Reperfusion Injury with a Combination of Anti-ICAM-1 and Anti- β_2 Integrin Monoclonal Antibodies", <i>Transplantation</i> , 62:1477-1485 (1996)
	* Edwards et al., "Mapping the Intercellular Adhesion Molecule-1 and -2 Binding Site on the Inserted Domain of Leukocyte Function-Associated Antigen-1", <i>J. Biol. Chem.</i> , 273:28937-28944 (1998)
	* Emelgh et al., "Small-Molecule Antagonists of LFA-1 Mediated Cell Adhesion", 221 st ACS Nat'l Mtg, San Diego, CA, USA:MEDI 256 (2001)
	* Fisher et al., "Identification of the Binding Site in Intercellular Adhesion Molecule 1 for Its Receptor, Leukocyte Function-Associated Antigen 1", <i>Mol. Biol. Cell</i> , 8:501-515 (1997)
	* Franke et al., "Synthetische Juvenilhoromone", <i>Helvetica Chimica Acta</i> , 58:268-278 (1975) (with unofficial English translation)

OMB No. 0651-0011

INFORMATION DISCLOSURE CITATION

Atty. Docket No.	09095.0006-01000	Appln. No.	10/725,212
Applicant	Indrani W. GUNAWARDANA		
Filing Date	December 1, 2003	Group:	1624

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
	* Gadek et al., "Identification and Characterization of Antagonists of the LFA-1/ICAM-1 Protein-Protein Interaction Novel Immunomodulatory Agents", <i>220th ACS Nat'l Mtg</i> , Washington, DC, USA: MEDI 177 (2000)
	* Gahmberg, C., "Leukocyte Adhesion: CD11/CD18 Integrins and Intercellular Adhesion Molecules", <i>Curr. Opin. Cell. Biol.</i> , 9:643-650 (1997)
	* Gahmberg, C.G., "Leukocyte Adhesion: Structure and Function of Human Leukocyte β_2 -Integrins and Their Cellular Ligands", <i>Eur. J. Biochem.</i> , 245:215-232 (1997)
	* Gorczynski et al., "A Role for Nonspecific (Cyclosporin A) or Specific (Monoclonal Antibodies to ICAM-1, LFA-1, and IL-10) Immunomodulation in the Prolongation of Skin Allografts After Antigen-Specific Pretransplant Immunization or Transfusion", <i>J. Immunol.</i> , 152:2011-2019 (1994)
	* Green et al., "T Cell Receptor Stimulation, but Not CD28 Costimulation, Is Dependent on LFA-1-Mediated Events", <i>Eur. J. Immunol.</i> , 24:265-272 (1994)
	* Gross et al., "Identification of LFA-1 as a Candidate Autoantigen in Treatment-Resistant Lyme Arthritis", <i>Science</i> , 281:703-706 (1998)
	* Gute et al., "Inflammatory Responses to Ischemia and Reperfusion in Skeletal Muscle", <i>Mol. Cell. Biochem.</i> , 179:169-187 (1998)
	* Hallahan et al., "Intercellular Adhesion Molecule 1 Knockout Abrogates Radiation Induced Pulmonary Inflammation", <i>PNAS</i> , 94:6432-6437 (1997)
	* Halloran et al., "Cellular Adhesion Molecules in Rat Adjuvant Arthritis", <i>Arthritis & Rheumatism</i> , 39:810-819 (1996)
	* Hamann et al., "Sterically Hindered Chelating Alkyl Phosphines Provide Large Rate Accelerations in Palladium-Catalyzed Animation of Aryl Iodides, Bromides, and Chlorides, and the First Amination of Aryl Tosylates", <i>J. Am. Chem. Soc.</i> , 120:7369-7370 (1998)
	* Hamilton et al., "Fluorenylalkanoic and Benzoic Acids as Novel Inhibitors of Cell Adhesion Processes in Leukocytes", <i>J. Med. Chem.</i> , 38:1650-1656 (1995)
	* Harning et al., "Reduction in the Severity of Graft-Versus-Host Disease and Increased Survival in Allogeneic Mice by Treatment with Monoclonal Antibodies to Cell Adhesion Antigens LFA-1 α and MALA-2", <i>Transplantation</i> , 52:842-845 (1991)
	* Hartman et al., "Protection of Ischemic/Reperfused Canine Myocardium by CL18/6, a Monoclonal Antibody to Adhesion Molecule ICAM-1", <i>Cardiovascular Res.</i> , 30:47-54 (1995)
	* Hasegawa et al., "Prevention of Autoimmune Insulin-Dependent Diabetes in Non-Obese Diabetic Mice by Anti-LFA-1 and Anti-ICAM-1 mAb", <i>Int'l Immunology</i> , 6:831-838 (1994)
	* He et al., "Effect of LFA-1 and ICAM-1 Antibody Treatment on Murine Corneal Allograft Survival", <i>Invest. Ophthalmol. Vis. Sci.</i> , 35:3218-3225 (1994)
	* Henricks et al., "Pharmacological Modulation of Cell Adhesion Molecules", <i>Eur. J. Pharmacol.</i> , 344:1-13 (1998)
	* Herold et al., "Prevention of Autoimmune Diabetes by Treatment with Anti-LFA-1 and Anti-ICAM-1 Monoclonal Antibodies", <i>Cell. Immunol.</i> , 157:489-500 (1994)

OMB No. 0651-0011

INFORMATION DISCLOSURE CITATION

Atty. Docket No.	09095.0006-01000	Appln. No.	10/725,212
Applicant	Indrani W. GUNAWARDANA		
Filing Date	December 1, 2003	Group:	1624

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	* Higuchi et al., <i>Pro-drugs as Novel Drug Delivery Systems</i> , ACS Symposium Series 14 (1975) (face pages and table of contents only)
	* Honda et al., "Deprotection of Allyl Groups With Sulfinic Acids and Palladium Catalyst", <i>J. Org. Chem.</i> , 62:8932-8936 (1997)
	* Horgan et al., "Role of ICAM-1 in Neutrophil-Mediated Lung Vascular Injury After Occlusion and Reperfusion", <i>Am. J. Physiol.</i> , 261:H1578-H1584 (1991)
	* Huang et al., "A Binding Interface on the I Domain of Lymphocyte Function-Associated Antigen-1 (LFA-1) Required for Specific Interaction with Intercellular Adhesion Molecule 1 (ICAM-1)", <i>J. Biol. Chem.</i> , 270:19008-19016 (1995)
	* Huth et al., "NMR and Mutagenesis Evidence for an I Domain Allosteric Site That Regulates Lymphocyte Function-Associated Antigen 1 Ligand Binding", <i>PNAS</i> , 97:5231-5326 (2000)
	* Isobe et al., "Specific Acceptance of Cardiac Allograft After Treatment with Antibodies to ICAM-1 and LFA-1", <i>Science</i> , 255:1125-1127 (1992)
	* Kakimoto et al., "The Effect of Anti-Adhesion Molecule Antibody on the Development of Collagen-Induced Arthritis", <i>Cell. Immunol.</i> , 142:326-337 (1992)
	* Kallen et al., "Structural Basis for LFA-1 Inhibition Upon Lovastatin Binding to the CD11a I-Domain", <i>J. Mol. Biol.</i> , 292:1-9 (1999)
	* Kawasaki et al., "Antibodies Against Intercellular Adhesion Molecule-1 and Lymphocyte Function-Associated Antigen-1 Prevent Glomerular Injury in Rat Experimental Crescentic Glomerulonephritis", <i>J. Immunol.</i> , 150:1074-1083 (1993)
	* Kelly et al., "Cutting Edge: A Small Molecule Antagonist of LFA-1-Mediated Cell Adhesion", <i>J. Immunol.</i> , 163:5173-5177 (1999)
	* Kishimoto et al., "Integrins, ICAMs and Selectins: Role and Regulation of Adhesion Molecules in Neutrophil Recruitment to Inflammatory Sites", <i>Advances Pharmacol.</i> , 25:117-169 (1994)
	* Knoerzer et al., "Clinical and Histological Assessment of Collagen-Induced Arthritis Progression in the Diabetes-Resistant BB/Wor Rat", <i>Toxicologic Pathol.</i> , 25:13-19 (1997)
	* Landis et al., "Involvement of the I Domain of LFA-1 in Selective Binding to Ligands ICAM-1 and ICAM-3", <i>J. Cell Biol.</i> , 126:529-537 (1994)
	* Lawrence et al., "Leukocytes Roll on a Selectin at Physiologic Flow Rates: Distinction from and Prerequisite for Adhesion through Integrins", <i>Cell</i> , 65:859-873 (1991)
	* Ley et al., "Lectin-Like Cell Adhesion Molecule 1 Mediates Leukocyte Rolling in Mesenteric Venules In Vivo", <i>Blood</i> , 77:2553-2555 (1991)
	* Link et al., "Discovery and SAR of Diarylsulfide Cyclopropylamide LFA-1/ICAM-1 Interaction Antagonists", <i>Bioorganic Medicinal Chem. Letters</i> , 11:973-976 (2001)
	* Liu, G., "Small Molecule Antagonists of the LFA-1/ICAM-1 Interaction as Potential Therapeutic Agents", <i>Expert Opin. Ther. Patents</i> , 11:1383-1393 (2001)

OMB No. 0651-0011

INFORMATION DISCLOSURE CITATION

Atty. Docket No.	09095.0006-01000	Appln. No.	10/725,212
Applicant	Indrani W. GUNAWARDANA		
Filing Date	December 1, 2003	Group:	1624

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	* Liu et al., "Novel μ -Arylthio Cinnamides as Antagonists of Leukocyte Function-Associated Antigen-1/Intracellular Adhesion Molecule-1 Interaction. 2. Mechanisms of Inhibition and Structure-Based Improvement of Pharmaceutical Properties", <i>J. Med. Chem.</i> , 44:1202-1210 (2001)
	* Liu et al., "Discovery of Novel μ -Arylthio Cinnamides as Antagonists of Leukocyte Function-Associated Antigen-1/Intracellular Adhesion Molecule-1 Interaction. 1. Identification of an Additional Binding Pocket Based on an Anilino Diaryl Sulfide Lead", <i>J. Med. Chem.</i> , 43:4025-4040 (2000)
	* Lu et al., "An Isolated, Surface-Expressed I Domain of the Integrin α LP2 is Sufficient for Strong Adhesive Function when Locked in the Open Conformation with a Disulfide Bond", <i>PNAS</i> , 98:2387-2392 (2001)
	* Miranda et al., "Thiols, Unsymmetrical Sulfides and Thioacetals from the New Reagent: Triisopropylsilanethiol", <i>Tetrahedron Letters</i> , 35:3221-3224 (1994)
	* Mulligan et al., "Compartmentalized Roles for Leukocytic Adhesion Molecules in Lung Inflammatory Injury", <i>J. Immunol.</i> , 154:1350-1363 (1995)
	* Nagase et al., "Intercellular Adhesion Molecule-1 Mediates Acid Aspiration-Induced Lung Injury", <i>Amer. J. Respir. Crit. Care Med.</i> , 154:504-510 (1996)
	* Nakanishi et al., "Transient Forebrain Ischemia Induces Increased Expression and Specific Localization of Cathepsins E and D in Rat Hippocampus and Neostriatum", <i>Exper. Neurology</i> , 121:215-223 (1993)
	* Nakao et al., "Monoclonal Antibodies Against ICAM-1 and LFA-1 Prolong Nerve Allograft Survival", <i>Muscle & Nerve</i> , 18:93-102 (1995)
	* Nakano, et al., "Adxanthromycins A and B, New Inhibitors of ICAM-1/LFA-1 Mediated Cell Adhesion Molecule from <i>Streptomyces</i> sp. NA-148", <i>J. Antibiotics.</i> , 53:12-18 (2000)
	* Old et al., "A Highly Active Catalyst for Palladium-Catalyzed Cross-Coupling Reactions: Room-Temperature Suzuki Couplings and Amination of Unactivated Aryl Chlorides", <i>J. Am. Chem. Soc.</i> , 120:9722-9723 (1998)
	* Oppenheimer-Marks et al., "Interleukin 15 is Produced by Endothelial Cells and Increases the Transendothelial Integration of T Cells In Vitro and in the SCID Mouse-Human Rheumatoid Arthritis Model In Vivo", <i>J. Clin. Invest.</i> , 101:1261-1272 (1998)
	* Oshiro et al., "Inhibition of Experimental Vasospasm with Anti-Intercellular Adhesion Molecule-1 Monoclonal Antibody in Rats", <i>Stroke</i> , 28:2031-2038 (1997)
	* Panés et al., "Role of Leukocyte-Endothelial Cell Adhesion in Radiation-Induced Microvascular Dysfunction in Rats", <i>Gastroenterology</i> , 108:1761-1769 (1995)
	* Pei et al., "Discovery of Potent Antagonists of Leukocyte Function-Associated Antigen-1/Intercellular Adhesion Molecule-1 Interaction. 3. Amide (C-Ring) Structure-Activity Relationship and Improvement of Overall Properties of Arylthio Cinnamides", <i>J. Med. Chem.</i> , 44:2913-2920 (2001)
	* Prescott D., "Lipid Vesicles as Carriers for Introducing Biologically Active Materials into Cells", <i>Methods in Cell Biology</i> , 14:33-71 (1976)

OMB No. 0651-0011

INFORMATION DISCLOSURE CITATION

Atty. Docket No.	09095.0006-01000	Appln. No.	10/725,212
Applicant	Indrani W. GUNAWARDANA		
Filing Date	December 1, 2003	Group:	1624

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
	* Qu et al., "The Role of the Divalent Cation in the Structure of the Domain I from the CD11a/CD18 Integrin", <i>Structure</i> , 4:931-942 (1996)
	* Roche E., "Bioreversible Carriers in Drug Design, Theory and Application", <i>Pergamon Press</i> (face page and press info only) (1987)
	* Sanfilippo P., "Novel Thiazole Based Heterocycles as Inhibitors of LFA-1/ICAM-1 Mediated Cell Adhesion", <i>J. Med. Chem.</i> , 38:1057-1059 (1995)
	* Schimmer et al., "Streptococcal Cell Wall-Induced Arthritis: Requirements for IL-4, IL-10, IFN- γ , and Monocyte Chemoattractant Protein-1", <i>J. Immunol.</i> , 160:1466-1471 (1998)
	* Springer T., "Traffic Signals for Lymphocyte Recirculation and Leukocyte Emigration: The Multistep Paradigm", <i>Cell</i> , 76:301-314 (1994)
	* Springer T., "Adhesion Receptors of the Immune System", <i>Nature</i> , 346:425-434 (1990)
	* Stanley et al., "The I Domain of Integrin LFA-1 Interacts with ICAM-1 Domain 1 at Residue Glu-34 But Not Gln-73", <i>J. Biol. Chem.</i> , 273:3358-3362 (1998)
	* Talento et al., "A Single Administration of LFA-1 Antibody Confers Prolonged Allograft Survival", <i>Transplantation</i> , 55:418-422 (1993)
	* Tamiya et al., "Protective Effect of Monoclonal Antibodies Against LFA-1 and ICAM-1 on Myocardial Reperfusion Injury Following Global Ischemia in Rat Hearts", <i>Immunopharmacology</i> , 29:53-63 (1995)
	* Tanaka et al., "Inhibition of Inflammatory Live Injury by a Monoclonal Antibody Against Lymphocyte Function-Associated Antigen-1", <i>J. Immunol.</i> , 151:5088-5095 (1993)
	* von Andrian et al., "Two-Step Model of Leukocyte-Endothelial Cell Interaction in Inflammation: Distinct Roles for LECAM-1 and the Leukocyte β_2 Integrins <i>In Vivo</i> ", <i>PNAS</i> , 88:7538-7542 (1991)
	* Wegner et al., "Intercellular Adhesion Molecule-1 Contributes to Pulmonary Oxygen Toxicity in Mice: Role of Leukocytes Revised", <i>Lung</i> , 170:267-279 (1992)
	* Wegner et al., "Intercellular Adhesion Molecule-1 (ICAM-1) in the Pathogenesis of Asthma", <i>Science</i> , 247:456-459 (1990)
	* Winn et al., "Discovery of Novel <i>p</i> -Arylthio Cinnamides as Antagonists of Leukocyte Function-Associated Antigen-1/Intercellular Adhesion Molecule-1 Interaction. 4. Structure-Activity Relationship of Substituents on the Benzene Ring of the Cinnamide", <i>J. Med. Chem.</i> , 44:4393-4403 (2001)
	* Wysong et al., "4-Aminopiperidine-4-carboxylic Acid: A Cyclic α,α -Disubstituted Amino Acid for Preparation of Water-Soluble Highly Helical Peptides", <i>J. Org. Chem.</i> , 61:7650-7651 (1996)
	* Zeng et al., "Inhibition of Transplant Rejection by Pretreatment of Xenogeneic Pancreatic Islet Cells with Anti-ICAM-1 Antibodies", <i>Transplantation</i> , 58:681-689 (1994)
	* Zhu et al., "Diels-Alder Reactions of Hexafluoro-2-butyne with 2-Heterosubstituted Furans: A Facile and General Synthesis of 1,4-Disubstituted 2,3-Di(trifluoromethyl) Benzenes", <i>Organic Letters</i> , 2:3345-3348 (2000)

OMB No. 0651-0011

INFORMATION DISCLOSURE CITATION

Atty. Docket No.	09095.0006-01000	Appln. No.	10/725,212
Applicant	Indrani W. GUNAWARDANA		
Filing Date	December 1, 2003	Group:	1624

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
	Clatterbuck et al., <i>J. Neurosurg.</i> , Vol. 97, pp. 676-82, 2002
	Clatterbuck et al., <i>J. Neurosurg.</i> , Vol. 99, pp. 376-382, 2003
	Pradilla et al., <i>J. Neurosurg.</i> , Vol. 101, pp. 88-91, 2004

Examiner	Date Considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
Form PTO 1449	Patent and Trademark Office - U.S. Department of Commerce